AI Terminal
BerGenBio
Report Publication Announcement • May 5, 2021
3555_rns_2021-05-05_0a74324e-3dcb-48e4-9208-f903e60cfb7d.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
BERGENBIO ASA: INVITATION TO PRESENTATION OF FIRST QUARTER 2021 RESULTS
Bergen, Norway, 5 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the first quarter 2021 on Wednesday 19 May 2021. A webcast presentation by BerGenBio's senior management team will take place at 10:00 am CET.
The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.
The first quarter report and presentation will be available on the Company's website in the Investors/Financial Reports section from 7:00 am CET the same day.
-Ends-
Contacts
Richard Godfrey CEO, BerGenBio ASA [email protected]
Rune Skeie, CFO, BerGenBio ASA [email protected]
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs
Consilium Strategic Communications [email protected] +44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux Advisers
[email protected] +47 995 13 891
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer, leukaemia and COVID-19. A first-in-class functional
blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com